Cerity Partners
ADPT icon

Cerity Partners’s Adaptive Biotechnologies ADPT Stock Holding History

Cerity Partners’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.58M Buy
446,559
+971
+0.2% +$14.9K 0.01% 789
2026
Q1 		$6.18M Sell
445,588
-67,281
-13% -$1.07M 0.01% 911
2025
Q4 		$8.33M Buy
512,869
+80,331
+19% +$1.31M 0.01% 717
2025
Q3 		$6.47M Sell
432,538
-22,198
-5% -$270K 0.01% 760
2025
Q2 		$5.3M Sell
454,736
-2,279
-0.5% -$20.7K 0.01% 779
2025
Q1 		$3.4M Sell
457,015
-21,433
-4% -$165K 0.01% 892
2024
Q4 		$2.48M Sell
478,448
-215,969
-31% -$1.19M 0.01% 1012
2024
Q3 		$3.56M Buy
694,417
+256,933
+59% +$1.12M 0.01% 849
2024
Q2 		$1.58M Sell
437,484
-238,760
-35% -$758K ﹤0.01% 1022
2024
Q1 		$2.17M Buy
676,244
+540,592
+399% +$2.09M 0.01% 935
2023
Q4 		$665K Buy
+135,652
New +$619K ﹤0.01% 1151
2023
Q3 		– Sell
-211,241
Closed -$1.42M – 1396
2023
Q2 		$1.42M Sell
211,241
-8,547
-4% -$63.6K 0.01% 818
2023
Q1 		$1.94M Buy
219,788
+61,523
+39% +$542K ﹤0.01% 732
2022
Q4 		$1.21M Sell
158,265
-319
-0.2% -$2.48K 0.01% 650
2022
Q3 		$1.13M Buy
158,584
+77,427
+95% +$729K 0.01% 487
2022
Q2 		$656K Buy
81,157
+3,223
+4% +$28.3K 0.01% 660
2022
Q1 		$1.08M Buy
77,934
+25,534
+49% +$401K 0.02% 432
2021
Q4 		$1.47M Sell
52,400
-19,684
-27% -$603K 0.02% 369
2021
Q3 		$2.45M Buy
72,084
+4,731
+7% +$171K 0.05% 239
2021
Q2 		$2.75M Buy
67,353
+10,527
+19% +$409K 0.06% 223
2021
Q1 		$2.29M Buy
56,826
+12,054
+27% +$652K 0.05% 236
2020
Q4 		$2.65M Sell
44,772
-167
-0.4% -$8.61K 0.08% 179
2020
Q3 		$2.19M Buy
44,939
+40,156
+840% +$1.69M 0.09% 158
2020
Q2 		$231K Buy
+4,783
New +$174K 0.01% 396

Other funds holding ADPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Cerity Partners's ADPT Position: Q2 2026 in Review

Cerity Partners increased its Adaptive Biotechnologies (ADPT) stake by 0.22% in Q2 2026, buying an estimated $14.9K and bringing the position to 446,559 shares worth $9.58M. The position accounts for 0.01% of the portfolio, ranked #789.

Cerity Partners first reported a position in ADPT in Q2 2020 and has held it in 24 quarters since. 280 funds tracked by Wall St. Rank hold ADPT as of Q2 2026.

  • Cerity Partners held 446,559 shares of Adaptive Biotechnologies worth $9.58M as of Q2 2026.
  • Cerity Partners bought 971 Adaptive Biotechnologies shares in Q2 2026, an estimated $14.9K.
  • Adaptive Biotechnologies made up 0.01% of Cerity Partners's portfolio in Q2 2026, its #789 holding.
  • Cerity Partners first reported a position in Adaptive Biotechnologies in Q2 2020 and has held it in 24 quarters since.
  • 280 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q2 2026.

Based on Cerity Partners's 13F filing for Q2 2026, filed 14 Aug 2026.